JNJ

227.58

+1.12%↑

UNH

366.5

+3.49%↑

TMO

470.15

+0.34%↑

ISRG

466.67

-0.89%↓

ABT

93.81

+1.03%↑

JNJ

227.58

+1.12%↑

UNH

366.5

+3.49%↑

TMO

470.15

+0.34%↑

ISRG

466.67

-0.89%↓

ABT

93.81

+1.03%↑

JNJ

227.58

+1.12%↑

UNH

366.5

+3.49%↑

TMO

470.15

+0.34%↑

ISRG

466.67

-0.89%↓

ABT

93.81

+1.03%↑

JNJ

227.58

+1.12%↑

UNH

366.5

+3.49%↑

TMO

470.15

+0.34%↑

ISRG

466.67

-0.89%↓

ABT

93.81

+1.03%↑

JNJ

227.58

+1.12%↑

UNH

366.5

+3.49%↑

TMO

470.15

+0.34%↑

ISRG

466.67

-0.89%↓

ABT

93.81

+1.03%↑

Strona główna・Stock List・AnaptysBio Inc

AnaptysBio Inc

Closed

SectorHealthcare

66.19 -0.78

Buy Sell

Overview

Share price change

24h

Current

Min

64.84

Max

70.88

Key metrics
By Trading Economics
Income	35M 50M
Sales	32M 108M
Profit margin	45.833
Employees	104
EBITDA	29M 68M

Recommendations
By TipRanks
Recommendations	Strong Buy
12 Months Forecast	+18.67% upside

Dividends
By Dow Jones
Next Earnings	1 maj 2026

Market Stats
By TradingEconomics
Market Cap	378M 1.9B
Previous open	66.97
Previous close	66.19

News Sentiment

By Acuity

75%

25%

330 / 348 Ranking in Healthcare

Technical Score

By Trading Central

Confidence

Strong Bearish Evidence

19.25 / 21.135 Support & Resistance

AnaptysBio Inc Chart

Wyniki osiągnięte w przeszłości nie są gwarantem przyszłych wyników.

Related News

28 kwi 2026, 23:33 UTC

Hot Stocks

Stocks to Watch: Robinhood, Visa, Seagate Technology, NXP Semiconductors

28 kwi 2026, 23:24 UTC

Earnings

Visa 2Q Revenue Climbs as Consumers Keep Spending; Board Authorizes $20 Billion Buyback -- Update

28 kwi 2026, 23:15 UTC

Major News Events

U.K. Economy to Suffer Large Loss of Output, Higher Inflation as Result of Middle East Conflict

28 kwi 2026, 22:46 UTC

Earnings

Booking Holdings Cuts Outlook as Middle East Conflict Weighs on Travel Demand -- Update

28 kwi 2026, 22:37 UTC

Earnings

Prudential PLC 1Q New Business Profit $686.0 Million, Up 10% on Year

28 kwi 2026, 22:15 UTC

Earnings

Major News Events

Mondelez Reports Developing Market Growth Offsetting U.S., Europe Weakness -- Update

28 kwi 2026, 23:33 UTC

Market Talk

Major News Events

Gold Edges Lower on Prospects of Dollar Strength -- Market Talk

28 kwi 2026, 23:31 UTC

Earnings

China Petroleum & Chemical 1Q Net Rose on Higher Crude Oil Prices >0386.HK

28 kwi 2026, 23:31 UTC

Earnings

China Petroleum & Chemical 1Q Capex Was CNY25.17B >0386.HK

28 kwi 2026, 23:30 UTC

Earnings

China Petroleum & Chemical 1Q Net CNY17.74B Vs. Net CNY13.98B >0386.HK

28 kwi 2026, 23:30 UTC

Earnings

China Petroleum & Chemical 1Q Rev CNY706.70B Vs. CNY735.36B >0386.HK

28 kwi 2026, 23:19 UTC

Market Talk

Earnings

Visa Points to Spending Boost from Tax Refunds in U.S. -- Market Talk

28 kwi 2026, 23:09 UTC

Earnings

Visa 2Q Revenue Climbs as Consumers Keep Spending; Board Authorizes $20B Buyback -- Update

28 kwi 2026, 23:03 UTC

Market Talk

Australia's Inflation Outlook Looks Pretty Grim -- Market Talk

28 kwi 2026, 23:01 UTC

Major News Events

NIESR Sees One Rate Rise to 4% in Benign Scenario

28 kwi 2026, 23:01 UTC

Major News Events

NIESR Sees U.K. Economy Growing by Just 0.5% in 'Adverse' Middle East Scenario

28 kwi 2026, 23:01 UTC

Major News Events

NIESR: BOE's Key Rate Should Rise to 5.25% in Adverse Scenario

28 kwi 2026, 23:01 UTC

Major News Events

U.K.'s NIESR Lowers 2026 U.K. Economic Growth Forecast to 0.9% From 1.4% in 'Benign' Scenario

28 kwi 2026, 23:01 UTC

Major News Events

NIESR Sees Inflation Peaking at Over 6% in Adverse Scenario

28 kwi 2026, 22:51 UTC

Earnings

Robinhood Earnings Fall Short. A Crypto Slump Is the Culprit. -- Barrons.com

28 kwi 2026, 22:48 UTC

Market Talk

Global Forex and Fixed Income Roundup: Market Talk

28 kwi 2026, 22:48 UTC

Market Talk

Australia's 1Q CPI Will Likely Provide Little Relief For RBA -- Market Talk

28 kwi 2026, 22:40 UTC

Market Talk

Major News Events

Australian 1Q CPI Will Likely Keep May Hike Alive -- Market Talk

28 kwi 2026, 22:32 UTC

Earnings

Booking Beats on Profit. Travel Demand Outlook Clouded By Iran War. -- Barrons.com

28 kwi 2026, 22:25 UTC

Acquisitions, Mergers, Takeovers

Pernod Ricard and Brown-Forman End Deal Talks -- Update

28 kwi 2026, 22:22 UTC

Earnings

Prudential PLC 1Q New Business Profit $686.0M, Up 10% on Year

28 kwi 2026, 22:17 UTC

Market Talk

Canada Fiscal Update Puts Central Bank on Track to Raise Rates -- Market Talk

28 kwi 2026, 22:14 UTC

Earnings

Prudential PLC 1Q APE Sales Up 6% on Year, to $1.823B >2378.HK

28 kwi 2026, 22:14 UTC

Earnings

Prudential PLC 1Q New Business Profit $686.0M, Up 10% on Year >2378.HK

28 kwi 2026, 22:07 UTC

Market Talk

Major News Events

Canada Chamber Frets Over Lost Fiscal Room -- Market Talk

Peer Comparison

Price change

AnaptysBio Inc Forecast

Price Target

By TipRanks

18.67% upside

12 Months Forecast

Average 78.45 USD 18.67%

High 140 USD

Low 50 USD

Based on 11 Wall Street analysts offering 12 month price targets forAnaptysBio Inc - Dist in the last 3 months.

Rating Consensus

By TipRanks

Strong Buy

11 ratings

Buy

Hold

Sell

Based on 11 analysts giving stock ratings to AnaptysBio Inc - Dist in the past 3 months.

Technical Score

By Trading Central

19.25 / 21.135Support & Resistance

Recent bearish events outweigh bullish events.

Recent bullish events outweigh bearish events.

The bullish and bearish events are balanced.

Sentiment

By Acuity

330 / 348 Ranking in Healthcare

Financials

Selling and administration expenses

Operating expenses

Pre-tax profit

Sales

Cost of sales

Gross profit on sales

Interest expense on debt

EBITDA

Operating profit

About AnaptysBio Inc

AnaptysBio, Inc., a clinical-stage biotechnology company, focuses in delivering immunology therapeutics. Its products include Rosnilimab, an IgG1 antibody that targets PD-1+ T cells, resulting in their agonism or depletion, broadly impacting pathogenic drivers of autoimmune and inflammatory diseases; and ANB032, a non-depleting antibody that binds to the BTLA checkpoint receptor and inhibits activated T cell proliferation; ANB033, a novel anti-CD122 antagonist antibody that targets the shared common beta subunit of the receptors for IL-15 and IL-2; ANB101, a BDCA2 modulator antibody that specifically targets plasmacytoid dendritic cells (pDCs); and Imsidolimab, an antibody that inhibits the interleukin-36 receptor, which is in the Phase 3 development for the treatment of generalized pustular psoriasis. The company also focuses on developing various antibody programs that are advanced to preclinical and clinical milestones under its collaborations. It has a collaboration and license agreement with GlaxoSmithKline, Inc. The company was formerly known as Anaptys Biosciences, Inc. and changed its name to AnaptysBio, Inc. in July 2006. AnaptysBio, Inc. was incorporated in 2005 and is based in San Diego, California.